|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL.: (2024.01) |
A61K 35/12 A61P 35/02 |
| (11) | Number of the document | 7127 |
| (13) | Kind of document | B |
| (21) | Application number | 2023 534 |
| (22) | Date of filing the application | 2023-08-30 |
| (41) | Date of publication of the application | 2024-12-10 |
| (45) | Date of publication of patent | 2025-03-10 |
| (30) | Number | Date | Country code |
| US63/497,185 | 2023-04-19 | US | |
| US63/504,184 | 2023-05-24 | US |
| (71) |
LEGEND BIOTECH USA INC.,
2101 Cottontail Lane, NJ 08873 Somerset,
US
JANSSEN BIOTECH, INC, 800/850 Ridgeview Drive, PA 19044 Horsham, US |
| (72) |
Nitin PATEL, US
Lida PACAUD, US Yuhong QIU, US Nikoletta LENDVAI, US William DERAEDT, BE Jordan Mark SCHECTER, US Ana Rute DE ASCENSAO SLAUGHTER, PG Carolina LONARDI, PA |
| (73) |
LEGEND BIOTECH USA INC.,
2101 Cottontail Lane, NJ 08873 Somerset,
US
JANSSEN BIOTECH, INC, 800/850 Ridgeview Drive, PA 19044 Horsham, US |
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA |
| Payment date | Validity (years) | Amount | |
| 2025-07-30 | 3 | 81.00 EUR |
| 2026-08-30 |